Five Prime Therapeutics, Inc. announced that initial data from GlaxoSmithKline’s ongoing Phase 1b clinical trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer and mesothelioma were featured today in an oral presentation by Dr. Pilar Garrido at the World Conference on Lung Cancer 2015 in Denver. The presentation titled, “FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor pathway deregulated squamous NSCLC or MPM,” included study data through August 5, 2015.
